Endeavor BioMedicines Entered into a License Agreement with Hummingbird Bioscience to HMBD-501 for HER3-Expressing Tumors
Shots:
- Hummingbird Bio will be eligible to receive up front and milestones of ~$430M along with royalties on net sales
- Endeavor gets an exclusive right to HMBD-501 (HER3-targeted ADC) to be developed for patients with HER3-expressing tumors with an exatecan payload that has been optimized for safety and efficacy
- HMBD-501 is a differentiated ADC that has been developed by Hummingbird Bio's Ab discovery and engineering platform and key state-of-the-art ADC technologies to enable a potentially enhanced efficacy and safety profile compared to previous generation ADCs. ENV-101 (Hedgehog signaling inhibitor) is currently being studied in the P-II studies for IPF
Ref: PR Newswire | Image: Hummingbird
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
